2020 American Society for Neural Therapy and Repair Conference
2020 American Society for Neural Therapy and Repair Conference
批准号:
10055563
负责人:
Kyle Fink
金额:
$2.5万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-04-01 至 2022-03-31
关键词:
Acute Brain InjuriesAcute DiseaseAddressAdultAffectAgeAlzheimer&aposs DiseaseAmericanAngelman SyndromeAreaAwardBasic ScienceBiotechnologyBrainBrain DiseasesCareer ChoiceCell TransplantationClinicalClinical TrialsCollaborationsCommittee MembersCreativenessDataDevelopmentDiagnosisDiseaseEducational workshopEmotionalEnsureEventExposure toFacultyFamilyFosteringFoundationsFundingGeneticGoalsGrantHuntington DiseaseIndustryInvestigationLeadLocalesMedicalMedical StudentsMethodsMissionNational Institute of Neurological Disorders and StrokeNervous System PhysiologyNeuraxisNeurodegenerative DisordersNeurodevelopmental DisorderNeurologicNeurologic DysfunctionsNeuronsNeuropharmacologyOutcome MeasureParkinson DiseasePatientsPhilosophyPopulationPostdoctoral FellowPrivatizationProceduresPublic HealthPublic Health Applications ResearchRecovery of FunctionRefractoryResearchResearch DesignResearch PersonnelRett SyndromeScienceScientistSenior ScientistSilicon DioxideSocial PlanningSocietiesSpinal Muscular AtrophySpinal cord injuryStrokeStudentsTechnologyTherapeuticTherapeutic exerciseTissue EngineeringTrainingTraining and EducationTranslatingTranslational ResearchTransplantationTraumatic Brain InjuryTravelUnited StatesUnited States National Institutes of HealthWagesWritingage related neurodegenerationbasecare costscohortcostdisabilitygene therapygraduate studentimprovedinsightmeetingsmembernervous system disorderneurogenesisneurotechnologynovelnovel therapeuticsnutritionprogramsrelating to nervous systemrepairedresponsesocioeconomicsstem cellssymposiumtooltranslational approachundergraduate student
中文摘要
神经退行性疾病,如阿尔茨海默病(AD)、亨廷顿病和帕金森病
(PD)、急性疾病,如创伤性脑损伤、脊髓损伤和中风,以及神经发育
诸如Angelman综合征、Rett综合征和脊髓性肌萎缩症的疾病属于
过多的破坏性神经系统疾病,几乎没有治疗方法。金融和
病人及其家属的情感负担是难以形容的;此外,护理费用和工资损失是
这对美国经济来说是一个巨大的财政负担。美国神经治疗与修复学会
(ASNTR)是一个专注于神经系统疾病的基础,转化和临床方面的协会。的
ASNTR成员使用细胞移植,基因治疗,组织工程,神经药理学,
其他尖端技术来研究和治疗这些疾病。
ASNTR的2020年年会将在佛罗里达州克利尔沃特海滩的喜来登沙礁举行。
提供了一个非常独特和亲密的环境,促进初级学员之间的互动,
有成就的调查人员,以及促进独特的合作。2020年会议将重点关注
未来十年神经修复和治疗的新方向,以及将新的
治疗因此,计划的会议将涵盖“干细胞编程”,“阿尔茨海默病”,一个实习生
组织了“谁,什么,哪里,何时移植”和“新兴神经技术”。办好第
为所有旅行奖获奖者和任何希望参加“冒险:
追求NINDS提供的转化研究机会”,将以来自
NINDS的翻译研究部门。此外,ASNTR对受训人员非常重视。
该协会鼓励学员参与ASNTR的治理,并专注于
实习生此R13的目的是为顶级学员(从提交的
摘要),以抵消其出席2020年会议的费用。此外,在2020年,我们有几个培训活动
计划好了我们还将为学员举办一次数据闪电战,以及与编辑见面的午餐会。而且我们
有计划的社交活动,旨在促进教师和学员之间的互动。ASNTR拥有强大的
我们在培养年轻研究人员方面有着良好的记录,我们的目标是继续沿着这一轨道前进。虽然我们总是
采取一切可用的方法(即接触生物技术行业和私人基金会),
对于受训人员的旅行支持,NIH的支持对于我们继续进行强大的培训至关重要
使命。
英文摘要
Neurodegenerative disorders such as Alzheimer's disease (AD), Huntington's disease and Parkinson's disease
(PD), acute disorders such as traumatic brain injury, spinal cord injury, and stroke, and neurodevelopmental
disorders such as Angelman's Syndrome, Rett Syndrome, and Spinal Muscular Atrophy are amongst a
plethora of devastating neurological conditions for which there are little to no treatments. The financial and
emotional burden to patients and their families is indescribable; in addition, the cost of care and lost wages is
an enormous financial liability for the US economy. The American Society for Neural Therapy and Repair
(ASNTR) is a society focused on basic, translational, and clinical aspects of neurological disorders. The
ASNTR membership uses cell transplantation, gene therapy, tissue engineering, neuropharmacology, and
other cutting-edge technologies to study and treat such disorders.
The 2020 annual meeting of ASNTR will be held at Sheraton Sand Key, Clearwater Beach, FL. This locale
provides for a very unique and intimate setting which promotes interactions between junior trainees and
accomplished investigators, as well as fostering unique collaborations. The 2020 meeting will be focused on
new directions in neural repair and therapy in the coming decade, and the challenges of translating new
therapies. As such, planned sessions will cover the “Stem Cell Programming”, “Alzheimer's Disease”, a trainee
organized “Who, What, Where, and When to Transplant” and “Emerging Neurotechnologies”. We will hold the
annual trainee session for all travel award winners and any member that wishes to attend “Taking the Plunge:
Pursuing Translational Research Opportunities available at NINDS” that will feature speakers from the
Department of Translational Research at NINDS. Moreover, ASNTR is tremendously committed to trainees.
The society encourages trainee participation in the governance of ASNTR and focuses on the development of
trainees. The purpose of this R13 is to garner travel support for top trainees (selected from submitted
abstracts) to offset their costs to attend the 2020 meeting. Moreover, in 2020 we have several trainee-activities
planned. We will also hold a data blitz for trainees as well as meet-the-editor luncheons. Moreover, we have
planned social events, aimed at furthering the interaction between faculty and trainees. ASNTR has a strong
track record of fostering young investigators, and we aim to continue in this trajectory. Although we always
pursue all methods available (i.e. approach the biotech industry and private foundations) in order to provide
travel support for trainees, support from the NIH is crucial in order for us to continue on our strong training
mission.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2019 AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR
-
批准号:9762479
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2019
-
负责人:Kyle Fink
-
依托单位:
MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE
-
批准号:10595651
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2017
-
负责人:Kyle Fink
-
依托单位:
MSCs engineered to produce Brain-Derived Neurotrophic Factor for the Treatment of Huntington's disease
-
批准号:9362838
-
项目类别:
-
资助金额:$63.02万
-
财政年份:2017
-
负责人:Kyle Fink
-
依托单位:
MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE
-
批准号:10443416
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2017
-
负责人:Kyle Fink
-
依托单位:
Novel epigenetic targets for silencing the Huntingtons disease mutation
-
批准号:8960294
-
项目类别:
-
资助金额:$5.24万
-
财政年份:2014
-
负责人:Kyle Fink
-
依托单位:
Novel epigenetic targets for silencing the Huntingtons disease mutation
-
批准号:8832937
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2014
-
负责人:Kyle Fink
-
依托单位:
海外基金